T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.51 NOK 1.21%
Market Cap: 617.1m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

EV/EBIT
Enterprise Value to EBIT

-27.4
Current
-2
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-27.4
=
Enterprise Value
555.7m NOK
/
EBIT
-20.3m NOK
All Countries
Close
Market Cap EV/EBIT
NO
Thor Medical ASA
OSE:TRMED
584.8m NOK -27.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 507.1
US
Abbvie Inc
NYSE:ABBV
315.4B USD 23.8
US
Amgen Inc
NASDAQ:AMGN
142B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD 23
US
Epizyme Inc
F:EPE
94.1B EUR -495.3
AU
CSL Ltd
ASX:CSL
139B AUD 25.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 17.6
US
Seagen Inc
F:SGT
39.3B EUR -52.4
NL
argenx SE
XBRU:ARGX
38.2B EUR -107.7
EBIT Growth EV/EBIT to Growth
NO
T
Thor Medical ASA
OSE:TRMED
Average EV/EBIT: 21.6
Negative Multiple: -27.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 507.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.5
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.3 N/A N/A
AU
CSL Ltd
ASX:CSL
25.1
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.7 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-8.3
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A